Welcome to our dedicated page for Atea Pharmaceuticals SEC filings (Ticker: AVIR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. Atea is a clinical-stage biopharmaceutical company focused on oral antiviral therapies for serious viral infections, and its filings help investors understand how it reports on clinical progress, financial condition and corporate governance.
Among the key documents are Form 8-K current reports, which Atea uses to announce material events such as quarterly financial results and related business updates. For example, 8-K filings dated August 7, 2025 and November 12, 2025 reference press releases detailing results of operations for the quarters ended June 30 and September 30, respectively, along with other matters described in those releases. These 8-Ks also confirm that Atea’s common stock is listed on The Nasdaq Global Select Market under the symbol AVIR.
Another important filing type is the proxy statement on Schedule 14A, summarized in a June 20, 2025 Form 8-K covering the company’s annual meeting of stockholders. That 8-K reports voting outcomes on the election of Class II directors, ratification of the independent registered public accounting firm and an advisory vote on executive compensation, providing insight into shareholder participation and governance decisions.
Through Stock Titan, users can track Atea’s ongoing Exchange Act reporting, including how it furnishes press releases as exhibits, discloses results of operations under Item 2.02 of Form 8-K, and reports shareholder meeting results under Item 5.07. Real-time updates from EDGAR are paired with AI-powered summaries that explain the structure and key points of filings, helping readers quickly identify items related to clinical-stage spending, cash balances, listing status on The Nasdaq Global Select Market and board or shareholder actions.
For those researching AVIR, this page offers a structured view of Atea’s regulatory history, from financial updates to governance matters, with tools to interpret the implications of each filing.
Atea Pharmaceuticals Inc Schedule 13G/A amendment shows The Vanguard Group reports 0 shares beneficially owned and 0% of Common Stock following an internal realignment. The filing states certain Vanguard subsidiaries will report holdings separately in reliance on SEC Release No. 34-39538, and Vanguard no longer is deemed to beneficially own those subsidiary-held securities.
Atea Pharmaceuticals, Inc. officer Andrea Corcoran exercised stock options to acquire 60,000 shares of common stock at an exercise price of $1.2400 per share. The option was fully vested and exercisable. Following the transaction, she directly holds 823,576 shares of Atea common stock.
Atea Pharmaceuticals, Inc. is a late-stage clinical biopharmaceutical company developing novel oral antivirals for serious viral diseases. Its lead program is a fixed-dose combination of bemnifosbuvir and ruzasvir for hepatitis C virus (HCV), positioned as a short-duration, pan‑genotypic, protease inhibitor‑free regimen.
Atea is running two large global Phase 3 trials, C‑BEYOND in the US/Canada and C‑FORWARD outside North America, each targeting about 880 treatment‑naïve HCV patients with and without compensated cirrhosis. C‑BEYOND is fully enrolled, with topline results expected mid‑2026, and C‑FORWARD topline data targeted for year‑end 2026, followed by a planned US NDA submission in March 2027.
The company is also advancing AT‑587, a nucleotide prodrug for chronic hepatitis E virus (HEV), with a first‑in‑human Phase 1 study planned for mid‑2026. Atea licenses ruzasvir from Merck under a global agreement that included a $25.0 million upfront payment, up to $135.0 million in development and regulatory milestones, up to $300.0 million in sales milestones, and tiered royalties from high single‑digit to mid‑teens percentages. Atea previously discontinued development of bemnifosbuvir for COVID‑19 after the Phase 3 SUNRISE‑3 trial did not meet its primary endpoint.
Atea Pharmaceuticals reported 2025 results showing continued investment in its hepatitis portfolio while narrowing its annual loss. Cash, cash equivalents and marketable securities were $301.8 million as of December 31, 2025, down from $454.7 million a year earlier, reflecting ongoing R&D spending.
For 2025, Atea recorded a net loss of $158.3 million, modestly improved from $168.4 million in 2024, with a basic and diluted net loss per share of $1.94. Research and development expenses were $148.0 million, slightly higher than 2024, driven by its Phase 3 HCV program, while general and administrative expenses declined to $32.9 million due mainly to lower stock-based compensation.
The company advanced its global Phase 3 HCV program for the fixed-dose combination of bemnifosbuvir and ruzasvir, completing enrollment in the North American C-BEYOND trial with over 880 patients and targeting topline results in 2026. It also expanded into hepatitis E with lead candidate AT-587, which is expected to enter clinical development in mid-2026.
BML Investment Partners, L.P. and Braden M. Leonard have reported a significant passive ownership stake in Atea Pharmaceuticals, Inc. common stock. As of 12/31/2025, they beneficially owned 7,810,000 shares, representing 9.9% of the outstanding common shares.
Leonard has sole voting and dispositive power over 320,000 shares and shared voting and dispositive power over 7,490,000 shares held by BML Investment Partners, L.P., of which he is the indirect controlling person. They certify the shares are held not for the purpose of changing or influencing control of Atea.
Atea Pharmaceuticals Chief Medical Officer Maria Arantxa Horga reported equity compensation activity involving common stock, restricted stock units (RSUs), and stock options. On January 31, 2026, 41,533 RSUs from a 124,600-unit grant and an additional 9,750 performance-based RSUs vested and were converted into common shares, after which no RSUs remained outstanding from these grants.
On the same date, 51,283 shares of common stock were acquired through an option or RSU-related transaction, and 16,073 shares of common stock were disposed of at $4.24 per share, leaving 96,086 common shares beneficially owned directly. Horga also received a new stock option for 173,500 shares at an exercise price of $4.24, vesting in 48 equal monthly installments starting after January 31, 2026 and becoming fully vested on January 31, 2030.
Atea Pharmaceuticals Chief Commercial Officer John Vavricka reported several equity transactions in the company’s stock. On January 31, 2026, he acquired 42,083 shares of common stock through the vesting and settlement of restricted stock units.
To cover tax obligations, 11,570 shares of common stock were withheld at a price of $4.24 per share, leaving him with 82,594 directly held shares. He also holds 82,508 shares indirectly as trustee of the John F. Vavricka Deed of Trust.
On the same date, Vavricka received a new grant of 119,520 stock options with a $4.24 exercise price. These options vest in 48 equal monthly installments after January 31, 2026 and will be fully vested by January 31, 2030.
Atea Pharmaceuticals Chief Development Officer Janet Hammond reported multiple equity award transactions. On January 31, 2026, 58,050 shares of common stock were acquired through RSU conversions, with 14,136 shares withheld at $4.24 per share to cover taxes, leaving 127,665 common shares directly held.
Concurrent with this, 46,800 RSUs from a 140,400-unit grant that fully vested by January 31, 2026, and 11,250 performance-based RSUs were settled into common stock, reducing RSU holdings to zero. Hammond also received a stock option for 177,000 shares at an exercise price of $4.24 per share, vesting in 48 equal monthly installments after January 31, 2026, and fully vesting on January 31, 2030.
Atea Pharmaceuticals officer Andrea Corcoran reported equity compensation activity. On January 31, 2026, previously granted restricted stock units converted into 54,866 shares of Atea common stock at no cash cost. To cover taxes, 16,104 of these shares were withheld at a price of $4.24 per share.
After these transactions, Corcoran directly owned 763,576 Atea common shares. She also received a new stock option covering 180,000 shares at an exercise price of $4.24 per share. This option vests in 48 equal monthly installments after January 31, 2026 and is fully vested by January 31, 2030.
Atea Pharmaceuticals President, CEO, and Chairman Jean-Pierre Sommadossi reported multiple equity award settlements and an option exercise. On January 31, 2026, 173,466 restricted stock units and 99,517 performance-based RSUs converted into common stock as previously granted awards fully vested.
Also on January 31, 2026, 106,093 shares of common stock were withheld at $4.24 per share to cover tax obligations, leaving 467,830 directly held shares. On February 3, 2026, he exercised a fully vested stock option for 300,000 shares at an exercise price of $1.24 per share, increasing his direct holdings to 767,830 shares. The filing also shows 5,866,025 shares held indirectly through JPM Partners LLC.